COVID-19 Vaccines: HHS Advisory Committee Urges ‘Great Caution’ On Use Of EUA

Biologics license application is preferred route to market, but if emergency authorization is given it should happen with full transparency and be communicated in a clear manner to strengthen public confidence, National Vaccine Advisory Committee says.

Caution_Tape
NVAC says great caution is warranted in granting emergency authorization to any COVID-19 vaccine. • Source: Shutterstock

The US Food and Drug Administration should exercise “great caution” in allowing a COVID-19 vaccine to be deployed through an emergency use authorization rather than through the preferred route of a biologics license application approval, the National Vaccine Advisory Committee said.

The preference for a BLA over an EUA is one of five recommendations NVAC mades in a letter to Brett...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet